AG˹ٷ

STOCK TITAN

[Form 4] FMC Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Jacqueline Scanlan, Executive VP & Chief HRO of FMC Corporation (FMC), reported a sale of 1,510 shares of FMC common stock on 08/18/2025 at a price of $37.49 per share, reducing her beneficial ownership to 36,834 shares. The filing indicates the transaction was made pursuant to a Rule 10b5-1 plan. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Jacqueline Scanlan, vicepresidente esecutiva e Chief HRO di FMC Corporation (FMC), ha venduto 1.510 azioni ordinarie FMC il 18/08/2025 al prezzo di $37,49 per azione, riducendo la sua partecipazione beneficiaria a 36.834 azioni. La comunicazione indica che l'operazione è stata effettuata ai sensi di un piano Rule 10b5-1. Il Modulo 4 è stato firmato da un procuratore il 19/08/2025.

Jacqueline Scanlan, vicepresidenta ejecutiva y Chief HRO de FMC Corporation (FMC), vendió 1.510 acciones ordinarias de FMC el 18/08/2025 a $37.49 por acción, reduciendo su participación beneficiaria a 36.834 acciones. La presentación indica que la transacción se realizó conforme a un plan Rule 10b5-1. El Formulario 4 fue firmado por un apoderado el 19/08/2025.

Jacqueline Scanlan, FMC Corporation (FMC)� 부사장 � 최고 인사 책임�(Chief HRO)� 2025-08-18� FMC 보통� 1,510주를 주당 $37.49� 매도하여 본인 실질 보유 주식� 36,834주로 줄였습니�. 제출서류에는 해당 거래가 Rule 10b5-1 계획� 따라 이루어졌다고 명시되어 있습니다. Form 4� 2025-08-19� 대리인(법정대리인)� 의해 서명되었습니�.

Jacqueline Scanlan, vice-présidente exécutive et Chief HRO de FMC Corporation (FMC), a déclaré la vente de 1 510 actions ordinaires FMC le 18/08/2025 au prix de 37,49 $ par action, réduisant sa participation bénéficiaire à 36 834 actions. Le dépôt indique que la transaction a été effectuée en vertu d'un plan Rule 10b5-1. Le formulaire 4 a été signé par un mandataire le 19/08/2025.

Jacqueline Scanlan, Executive VP & Chief HRO von FMC Corporation (FMC), meldete am 18.08.2025 den Verkauf von 1.510 Stück FMC-Stammaktien zum Preis von $37,49 je Aktie und verringerte damit ihr wirtschaftliches Eigentum auf 36.834 Aktien. Die Meldung gibt an, dass die Transaktion im Rahmen eines Rule 10b5-1-Plans erfolgte. Das Formular 4 wurde am 19.08.2025 von einem Bevollmächtigten unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Insider sale of 1,510 shares via a 10b5-1 plan; small relative holding change, likely routine liquidity.

The sale of 1,510 shares at $37.49 is disclosed transparently and flagged as executed under a Rule 10b5-1 plan, which typically indicates a prearranged, non-discretionary trade. The remaining beneficial position of 36,834 shares provides context on her total exposure to FMC equity. There are no derivative transactions or other material changes reported. For investors, this represents routine insider selling rather than a material corporate development.

TL;DR Filing shows compliance with Section 16 disclosure rules and use of a 10b5-1 plan; no governance concerns apparent from this Form 4.

The Form 4 is properly completed: it identifies the reporting person, relationship to the issuer, transaction type, price, and post-transaction ownership. The checked 10b5-1 box and attorney-in-fact signature indicate adherence to procedural controls for insider transactions. There is no indication of undisclosed related-party transactions or amendments. This appears to be a routine, compliant insider sale.

Jacqueline Scanlan, vicepresidente esecutiva e Chief HRO di FMC Corporation (FMC), ha venduto 1.510 azioni ordinarie FMC il 18/08/2025 al prezzo di $37,49 per azione, riducendo la sua partecipazione beneficiaria a 36.834 azioni. La comunicazione indica che l'operazione è stata effettuata ai sensi di un piano Rule 10b5-1. Il Modulo 4 è stato firmato da un procuratore il 19/08/2025.

Jacqueline Scanlan, vicepresidenta ejecutiva y Chief HRO de FMC Corporation (FMC), vendió 1.510 acciones ordinarias de FMC el 18/08/2025 a $37.49 por acción, reduciendo su participación beneficiaria a 36.834 acciones. La presentación indica que la transacción se realizó conforme a un plan Rule 10b5-1. El Formulario 4 fue firmado por un apoderado el 19/08/2025.

Jacqueline Scanlan, FMC Corporation (FMC)� 부사장 � 최고 인사 책임�(Chief HRO)� 2025-08-18� FMC 보통� 1,510주를 주당 $37.49� 매도하여 본인 실질 보유 주식� 36,834주로 줄였습니�. 제출서류에는 해당 거래가 Rule 10b5-1 계획� 따라 이루어졌다고 명시되어 있습니다. Form 4� 2025-08-19� 대리인(법정대리인)� 의해 서명되었습니�.

Jacqueline Scanlan, vice-présidente exécutive et Chief HRO de FMC Corporation (FMC), a déclaré la vente de 1 510 actions ordinaires FMC le 18/08/2025 au prix de 37,49 $ par action, réduisant sa participation bénéficiaire à 36 834 actions. Le dépôt indique que la transaction a été effectuée en vertu d'un plan Rule 10b5-1. Le formulaire 4 a été signé par un mandataire le 19/08/2025.

Jacqueline Scanlan, Executive VP & Chief HRO von FMC Corporation (FMC), meldete am 18.08.2025 den Verkauf von 1.510 Stück FMC-Stammaktien zum Preis von $37,49 je Aktie und verringerte damit ihr wirtschaftliches Eigentum auf 36.834 Aktien. Die Meldung gibt an, dass die Transaktion im Rahmen eines Rule 10b5-1-Plans erfolgte. Das Formular 4 wurde am 19.08.2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scanlan Jacqueline

(Last) (First) (Middle)
C/O FMC CORPORATION
2929 WALNUT STREET

(Street)
PHILADELPHIA PA 19104

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
FMC CORP [ FMC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive VP & Chief HRO
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/18/2025 S 1,510 D $37.49 36,834 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Sara V. Ponessa, as attorney-in-fact for Jacqueline Scanlan 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Fmc Corp

NYSE:FMC

FMC Rankings

FMC Latest News

FMC Latest SEC Filings

FMC Stock Data

4.74B
123.73M
0.93%
96.93%
5.04%
Agricultural Inputs
Chemicals & Allied Products
United States
PHILADELPHIA